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Abstract
Emotional lability, or sudden strong shifts in emotion, commonly occurs in youth with attention-
deficit/hyperactivity disorder. Although these symptoms are impairing and disruptive, relatively 
little research has addressed their treatment, likely due to the difficulty of reliable and valid 
assessment. Promising signals for symptom improvement have come from recent studies using 
stimulants in adults, children and adolescents. Similarly, neuroimaging studies have begun to 
identify neurobiological mechanisms underlying stimulants’ impact on emotion regulation 
capacities. Here, we review these recent clinical and neuroimaging findings, as well as 
neurocognitive models for emotional lability in ADHD, issues of relevance to prescribers and the 
important role of psychiatric comorbidity with treatment choices.
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INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD) is among the most commonly diagnosed 
pediatric psychiatric disorders, affecting 3–10% of school age children [1]. Although the 
diagnostic criteria of ADHD include inattention, hyperactivity, and impulsivity, many 
children with ADHD also demonstrate significant levels of emotional lability [2]. The term, 
emotional lability, has many possible connotations, but here we are referring to sudden, 
strong shifts in emotions that are inappropriate to the setting or the child’s developmental 
stage [3, 4]. Children with high levels of emotional lability have been shown to tolerate 
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frustration poorly, have high levels of irritability and demonstrate frequent crying spells or 
tantrums [2]. Emotional lability may also be associated with an over-expression of positive 
emotions such as exuberance, excitability, and energy that are disproportionate to the 
eliciting circumstance, and can be off-putting to peers [5, 6]. These emotional reactions, 
both for positive and negative emotions, are typically brief in duration, lasting on the order 
of minutes to hours, rather than days to weeks, and thus differ from emotional lability 
associated with bipolar spectrum disorders, which are characterized by protracted episodes 
(e.g., days-weeks) of low or high emotional states. Emotional lability in ADHD may, 
however, overlap diagnostically with disruptive mood dysregulation (DMDD) [7] or “severe 
mood dysregulation,” both of which are characterized by chronic temper outbursts [2, 8]. In 
one epidemiologic survey, 30.8% of youth with DMDD also met criteria for ADHD [9], 
highlighting the significant overlap between these diagnostic constructs.
The prevalence of emotional lability in children with ADHD has been examined in several 
clinical and population based studies. In a study of 5,326 children with ADHD, Stringaris 
and colleagues [10] found that parents reported impairing levels of emotional lability 
(termed “mood lability” in this study) in 38% of the sample. Using a clinical sample, Becker 
and colleagues [11] reported a slightly higher rate, with 40–49% of children with ADHD 
having elevated levels of parent-reported emotional symptoms (symptoms similar to 
emotional lability). Based on the emotional lability subscale of the Parent and Teacher 
Conners’ ADHD rating scale, Sobanski and colleagues [2] found that in a clinical sample of 
1186 children with ADHD, 25% had severe levels of emotional lability and an additional 
50% had moderate levels. Differing assessment tools and study samples have likely 
contributed to the broad range in prevalence estimates of emotional lability in ADHD.
Impairments specifically linked to emotional lability in ADHD have been reported in several 
longitudinal studies [2, 12]. Barkley and colleagues [13] examined the effects of emotional 
lability (which the authors termed “emotional impulsiveness”) on 135 children with ADHD 
followed into adulthood. After controlling for the influence of hyperactive/impulsive and 
inattentive symptoms, the study found that emotional lability independently contributed to 
higher rates of incarceration, poorer academic achievement, more driving accidents, and 
more problematic poor social and marital relations. Moreover, emotional lability was found 
to have a larger effect on patients’ overall impairment than hyperactive/impulsive symptoms 
[13]. Studies have also shown that the presence of emotional lability in hyperactive children 
is associated with more severe ADHD symptoms, more frequent comorbid disorders, and 
higher rates of substance use disorders [2, 14, 15].
NEUROBIOLOGICAL MODELS OF EMOTIONAL LABILITY IN ADHD
Two competing hypotheses have been advanced to explain the neurobiological bases of 
emotional lability in ADHD [3, 16, 17]. (Though other hypotheses have been offered, we 
focus here on the two most widely cited perspectives.) The first, which we have termed the 
“dyscontrol hypothesis,” attributes emotional lability in ADHD primarily to impairments in 
executive control [18]. With this view, emotional lability represents an impaired capacity to 
suppress responses triggered by emotional stimuli [19]. According to the dyscontrol 
hypothesis, emotional processing is largely normal in children with ADHD; however, 
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hyperactive children are impaired in their capacity to down-regulate, or inhibit, emotional 
responses and thus manifest highly emotional behaviors and reactions. This is a 
parsimonious hypothesis in that impairments in executive functions are well documented in 
ADHD [20]. The dyscontrol hypothesis can thus be folded into existing neurocognitive 
models of ADHD as an additional manifestation of a disorder of executive functions.
Empirical support for the dyscontrol hypothesis, however, is somewhat lacking. As Nigg 
and colleagues [21] have pointed out, most children with ADHD do not manifest 
impairment on any given executive function measure. Moreover, recent functional 
neuroimaging studies have examined emotional processing and lability in children with 
ADHD [22–24]. These studies have consisted of relatively small samples and require 
replication, but nonetheless, suggest that anomalies within frontolimbic circuits, which are 
not typically associated with executive functions, may underlie emotional lability in children 
with ADHD.
An opposing hypothesis, which we term the “affectivity hypothesis,” maintains that 
emotional lability in children with ADHD emerges not from impaired executive functions, 
but rather through the more direct route of dysfunctional emotional processing itself. 
Emotional stimuli, according to the affectivity hypothesis, elicit inordinately strong 
emotional responses in children with ADHD [25]. According to the affectivity hypothesis, it 
is not the regulation of emotion that is impaired, but rather the production of the emotional 
response itself that is abnormally robust.
The affectivity hypothesis has received less research and clinical focus than the dyscontrol 
hypothesis perhaps because ADHD is conceptualized largely as a cognitive, or non-affective 
disorder. Within this paradigm, the dyscontrol hypothesis offers a more integrated 
explanation of emotional lability in ADHD than does the affectivity hypothesis. The 
dyscontrol hypothesis views emotional lability as an outgrowth of impaired executive 
functions, which are viewed as a component of attention, broadly defined. The dyscontrol 
hypothesis thus provides a heuristic model for the overt emotionality, while maintaining an 
emphasis on attentional impairments [18]. Conversely, the affectivity hypothesis broadens 
the lens into the pathophysiology of ADHD by emphasizing the importance of 
neurobiological systems underling emotional processing, in addition to attentional control 
and executive functions [22].
The central role of an attentional deficit in ADHD has been questioned by recent 
neuropsychological studies [21, 26] in which demonstrable, consistent impairments in 
sustained focus have been difficult to demonstrate, at least in the laboratory setting. This has 
led some authors to challenge the prevailing conceptualization of ADHD as a primarily 
cognitive disorder.
A parallel debate persists over how stimulants attenuate emotional lability in children with 
ADHD [3]. Stimulants may enhance executive control, thereby enhancing children’s ability 
to suppress emotional responses. Conversely, stimulants may have a more direct salutary 
effect on emotional processing, such that emotional stimuli elicit a more modest response. 
Neuroimaging studies have only begun to test these competing hypotheses, but preliminary 
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studies suggest that stimulants may attenuate atypical emotional processing in regions 
associated with emotion including the amygdala and medial prefrontal cortex [3, 27] and 
through improvements in regions associated with inhibitory control, such as the inferior 
frontal gyrus [28]. Such findings are supportive of both hypotheses, suggesting that 
stimulants may have a direct salutary effect on emotional processing regions and regions 
traditionally associated with more cognitive functions, that may influence emotion 
regulation. However, these findings need replication with larger samples, tasks capable of 
probing emotional lability and placebo-controlled, longitudinal designs.
Stimulant Effects on Emotional Lability
Though debate persists over the neural mechanisms by which stimulants improve emotional 
lability, clinical experience has long suggested that stimulants can have positive, favorable 
effects on emotional lability. In Charles Bradley’s historic studies of benzedrine (the first 
studies documenting stimulants’ beneficial effects in children), he noted that the children he 
treated had greater “control…over the expression of their emotions” [29]. Similar anecdotal 
reports are well represented in literature [30, 31].
Despite anecdotal support, empirical support for stimulant effects on emotional lability is 
less robust. The paucity of empirical support for stimulant effects on emotional lability 
stands in stark contrast with the numerous, randomized clinical trials demonstrating 
stimulant’s short term efficacy on the diagnostic symptoms of ADHD [32, 33]. This 
disparity in empirical support may, to some extent, reflect the lack of reliable assessment 
instruments for monitoring treatment related improvements in emotional lability. Whereas 
several well-validated, parent- and teacher-report instruments are available to assess 
diagnostic symptoms of ADHD, few instruments have been developed for similarly 
assessing emotional lability. The lack of reliable and valid instruments to assess emotional 
lability makes it challenging to design randomized clinical trials to test stimulant effects on 
emotional lability. Nonetheless, five randomized, double blind, placebo-controlled trials of 
stimulant treatment in children or adults with ADHD in which emotional lability (or similar 
constructs) was a reported outcome measure have been published (Table 1).
The largest study was a multi-center, double-blind, randomized, parallel group, placebo-
controlled trial involving 363 adults with ADHD [34]. Following 24 weeks of treatment 
with extended release methylphenidate (MPH-ER), there was a significant reduction in 
emotional lability, as assessed by the emotional dysregulation items on the Wender-
Reimherr Adult ADHD Scale [35]. The effect size ranged from 0.28 to 0.4, which is lower 
than stimulants’ effect size on diagnostic ADHD symptoms (meta-analyses suggest a range 
of 0.6–0.8 [36, 37]), but it is still clinically significant. Other placebo-controlled trials of 
methylphenidate in adults with ADHD similarly report improvements in emotional lability 
(Table 1) with larger effect sizes of up to 0.7 [38, 39]. More recently, in a randomized, 
double-blind, placebo-controlled efficacy study of lisdexamfetamine (LDEX), Childress et 
al [40] reported a significant improvement in emotional lability in the LDEX-treated 
children with ADHD and high levels of emotional lability. The sample consisted of 283 
children with ADHD and emotional lability, who were assessed by parent report on the 
Conners’ ADHD rating scale [40]. Another study in children examined the 
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neuropsychological and clinical effects of methylphenidate in 75 boys with ADHD treated 
in a 12-week, placebo-controlled, double-blinded, crossover trial [41]. Significant reductions 
in emotional lability were noted on the emotional lability subscale of the Conners’ Parent 
and Teacher ADHD rating scale. Effect sizes ranged from 0.42–0.46 and 0.45–0.79 for 
parent and teacher reports, respectively.
Stimulant-Induced Irritability
Clinical decision making in regards to emotional lability is complicated by the fact that 
exacerbation of irritability is a reported side effect of stimulant treatment [42, 43]. Whereas 
improvement in emotional lability can be expected for many patients with ADHD, in a small 
minority, stimulants can induce or worsen emotional lability, through increases in 
irritability. Prior to initiating treatment with a stimulant, careful discussion of this potential 
side effect is warranted. Additionally, clinicians need to consider that stimulants can have 
withdrawal effects as blood serum levels begin to decline. For example, some patients 
experience increases in irritability and poor frustration tolerance, termed “rebound 
irritability.” These withdrawal effects need to be differentiated from stimulant-induced 
emotional lability. This typically can be discerned based on the timing of the symptoms – 
withdrawal effects occur toward the end of the stimulant’s duration of action, whereas 
stimulant-induced emotional lability typically occurs as stimulant levels are peaking. 
Making this distinction has clinical importance because withdrawal effects can often be 
alleviated with low doses of a short-acting stimulant administered in the afternoon as the 
morning dose of stimulant is waning. Conversely, stimulant-induced emotional lability may 
require discontinuing or switching medications. Recent work suggests that the majority of 
parents who report that their child is unable to tolerate stimulant medications due to 
irritability, are misattributing rebound irritability or lack of efficacy to stimulant-induced 
irritability [44].
In sum, whereas stimulants’ efficacy in reducing the diagnostic symptoms of ADHD has 
been repeatedly demonstrated, studies of stimulant effects on emotional lability, though 
suggestive, are far less numerous. Further replication, particularly in pediatric samples, is 
needed, as are long-term follow up studies to determine whether stimulant-induced 
reductions in emotional lability are sustained and whether the negative outcomes associated 
with ADHD are reduced. Of particular concern are youth whose emotional lability is 
refractory to stimulant treatment. Clinicians are often left treating these children with agents 
that have limited empirical support in this population, such as mood stabilizers and atypical 
antipsychotics. Developing more reliable and valid symptom scales and neuropsychological 
measures of emotional lability would facilitate conducting more clinical trials aimed at 
examining stimulant effects on emotional lability. Lastly, neurobiological studies using 
brain-imaging techniques can help clarify the neurobiological basis of emotional lability in 
ADHD with the goal of providing targets for novel treatment development. Novel 
interventions are particularly needed for youth struggling with emotional lability that is 
refractory to stimulant and other available treatments.
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ADHD and Anxiety
In addition to emotional lability, many youth with ADHD also struggle with significant 
levels of anxiety, and between 20 – 40% have a comorbid anxiety disorder [45, 46]. A 
treatment concern related to emotional lability is whether children and adolescents with both 
ADHD and significant anxiety have a differential response to stimulants compared to 
individuals with ADHD alone. Furthermore, does the presence of a comorbid anxiety 
disorder interfere with the response of ADHD symptoms to stimulant treatment? If the 
presence of an anxiety disorder deters the efficacy of stimulant treatment, this would suggest 
that clinicians should consider a different treatment algorithm for ADHD when anxiety is 
present.
Anxiety associated with ADHD may emerge from an inability to function in daily life due to 
the social and cognitive limitations associated with ADHD. This type of anxiety may differ 
etiologically from the worry and phobic behaviors characteristic of a primary anxiety 
disorder [47]. Alternatively, emotion regulation deficits that lead to emotional lability could 
also predispose to anxiety disorders in a subset of youth with ADHD. If this hypothesis 
linking emotional lability with anxiety disorders were validated, co-occurring treatment of 
both disorders might be possible with stimulant treatment alone. To date, this question has 
not been experimentally probed. However, several studies from the late 1980s/early 1990s 
suggested that some children and adolescents with ADHD and comorbid anxiety disorders 
were less responsive to stimulant treatment than children with ADHD alone, for treatment of 
core AHDH symptoms [48, 49]. Children with comorbid anxiety also had higher rates of 
side effects, including tics, although there was no evidence that stimulants worsened 
symptoms of either ADHD or anxiety. Treatment of emotion-related symptoms, either 
anxiety or emotional lability, was not addressed in these studies.
Impairments in working memory, a subset of executive functioning, have been linked to 
ADHD [50]. Stimulants are believed to not only reduce hyperactivity, but also increase 
aspects of cognitive processing including working memory, which allows an individual to 
hold and manipulate information while planning and carrying out a task. Tannock and 
colleagues [51] demonstrated that even a single dose of MPH improved tasks of verbal–
auditory working memory (digit span forward and backward) in non-anxious children with 
ADHD, whereas there were no beneficial effects on those with ADHD and comorbid 
anxiety. A more recent study showed that MPH had moderate but beneficial effects on 
selective aspects of verbal–auditory working memory and on a visual-spatial working 
memory in children with ADHD but showed no such improvements in children with ADHD 
and anxiety [52]. However, there was again no evidence that stimulants worsened either 
behavioral or cognitive responses in participants with ADHD and anxiety [52]. This is in 
contrast to anecdotal reports suggesting that stimulant treatment in children with both 
ADHD and significant anxiety may exacerbate symptoms across diagnostic domains, 
anxiety and ADHD.
Additional studies suggest that co-morbid anxiety neither interferes in the response to 
stimulants on diagnostic symptoms of ADHD, nor increases side effects. Diamond and 
colleagues [53] randomized 91 children with ADHD and ADHD + anxiety to an acute and 
clinically applicable titration trial of MPH, followed by a four-month extended trial. 
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Subjects with and without anxiety responded equally well to the stimulant, and there were 
no differences in side effects between groups. Most notably, in the Multimodal Treatment 
Study (MTA)[32], 579 children with ADHD were randomized to community treatment, 
intensive behavioral intervention, medication management, or a combination of medication 
management and behavioral intervention. Children with ADHD and anxiety showed an 
equally positive response to MPH as those children with ADHD without anxiety [32]. 
Children with ADHD and anxiety, however, showed a more pronounced response when 
treated with MPH combined with the behavioral intervention. Therefore, when treating a 
child with ADHD and comorbid anxiety, clinicians may consider adding a psychosocial 
treatment to the psychopharmacological intervention.
When treating patients with both ADHD and anxiety, a fundamental question regarding 
pharmacotherapy is whether the initial treatment should target ADHD or anxiety symptoms, 
or potentially both with a single pharmacologic agent. The American Academy of Pediatrics 
(AAP) Clinical Practice Guidelines for the diagnosis and treatment of ADHD[54] note that 
clinicians must first consider whether ADHD symptoms are the manifestation of another 
condition such as an anxiety disorder or if they indicate a discrete diagnosis of ADHD. A 
thorough clinical and development history, as well as assessment of ADHD symptoms in 
varied settings (e.g., home and school) is critical to making this distinction. If the diagnosis 
of ADHD is confirmed, the AAP guidelines note that appropriate treatment of ADHD can 
result in the resolution of comorbid symptoms such as anxiety [54]. Similarly, the Texas 
Children’s Medication Algorithm Project (CMAP), a consensus conference that developed 
treatment algorithms for the pharmacotherapy of ADHD and comorbid conditions, suggests 
that if a child has ADHD and anxiety, treatment should begin with either a stimulant or 
atomoxetine (Strattera) [55]. The addition of a second pharmacological agent, such as an 
SSRI, should be considered when monotherapy does not produce adequate symptom 
improvement.
CONCLUSIONS
Although emotional lability is an associated feature common in ADHD, relatively little 
research has focused on treatments to address this impairing symptom in children and 
adolescents. Recent studies, some in adults, have utilized assessment tools capable of valid 
and reliable monitoring of emotional lability across treatment. These studies are uniformly 
supportive of stimulant use to treat emotional lability in ADHD, although certainly in youth, 
additional research to validate these findings is needed. Of note, few concerns for induction 
of irritability in stimulant treated youth in these studies were raised. Neurobiological models 
explaining how stimulant use can improve emotional lability have begun to be tested and 
suggest mechanisms consistent with both effects on emotion regulatory brain regions as well 
as general improvements in inhibitory control regions, which impact emotion as well as 
cognition. Future work is needed to further refine these neurobiological mechanisms, using 
larger samples and placebo-controlled designs. In addition, while stimulant treatments for 
emotional lability appear promising, there remains a need to address treatment strategies for 
stimulant refractory youth, to address the issue of treating emotional lability outside of the 
context of ADHD and to identify evidence-based practices for augmentation agents for 
partial responders. Finally, the mechanistic relationship with comorbidities (e.g., emotional 
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lability and anxiety disorders) needs further empirical exploration. If a causal link between 2 
symptom clusters were to be identified, such a link would drive treatment decisions, both 
toward and away from stimulant use.
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